LGALS3 and Hepatic fibrosis: In a toxin-induced liver fibrosis murine model, the galectin-3 inhibitors galactoarabino-rhamnogalaturonan (GR-MD-02) and galactomannan (GM-CT-01) both tend to reduce the galectin-3 activity in the portal as well as septal macrophages, attenuate hepatic fibrosis, reverse hepatic cirrhosis, and reduce portal pressure [74].